ArticlePloS one2014
Increase in nontuberculous mycobacteria isolated in Shanghai, China: results from a population-based study.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Prevalence ofFrontiers in microbiology · 2024Pooled it
- Trial
- Clinical features of nontuberculous mycobacteria and diagnosis with nanopore targeted sequencing: a retrospective cohort study.Annals of clinical microbiology and antimicrobials · 2026Article
- Clinical characteristics, antimicrobial susceptibility patterns, and treatment outcomes of nontuberculous mycobacterial diseases in eastern China: a retrospective cohort study (2019-2022).Microbiology spectrum · 2026Article
- Clinical utility of targeted next-generation sequencing for rapid detection, species differentiation, drug resistance profiling, and prognostic evaluation inFrontiers in cellular and infection microbiology · 2026Article
- Diagnostic accuracy and clinical impact of DNA microarray chip in pulmonary mycobacterial infections: a retrospective cohort study.BMC infectious diseases · 2025Article
- Distribution and epidemiological characteristics of nontuberculous mycobacterium species in jianghan plain.Scientific reports · 2025Article
- Negligible clinical impact of subsequent non-tuberculous mycobacteria isolation during MDR/RR-TB treatment: a 9-year retrospective cohort study from Wenzhou, China.BMC infectious diseases · 2025Article
- The Intriguing Pattern of Nontuberculous Mycobacteria in Bulgaria and Description ofInternational journal of molecular sciences · 2024Article
- Prevalence of nontuberculous mycobacteria and the emergence of rare species in Henan Province, China.Epidemiology and infection · 2024Article
- Analysis of Clinical Isolation Characteristics of Nontuberculous Mycobacteria and Drug Sensitivity of Rapidly Growing Mycobacteria in the General Hospital of Guangzhou, China.Infection and drug resistance · 2024Article
- Plasma cytokine levels as markers of pathogenesis and treatment response in patients with non-tuberculous mycobacterial pulmonary disease.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Global Epidemiology of Nontuberculous Mycobacterial Pulmonary Disease: A Review.Clinics in chest medicine · 2023Review
- Multiple Bone Destruction Secondary toDiagnostics (Basel, Switzerland) · 2023Article
- Mycobacterium Avium Complex Infection of the Spine in a Patient Without Acquired Immune Deficiency Syndrome: A Case Report and Literature Review.Orthopaedic surgery · 2023Review
- Molecular Identification of Non-tuberculous Mycobacteria in Suspected Tuberculosis Cases in Central India.Cureus · 2023Article
- First Case Reports of Nontuberculous Mycobacterial (NTM) Lung Disease in Ecuador: Important Lessons to Learn.Pathogens (Basel, Switzerland) · 2023Article
- Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020.Tuberculosis and respiratory diseases · 2023Article
- Epidemiology of Nontuberculous Mycobacteria in Tuberculosis suspects, Southwest of China, 2017-2022.Frontiers in cellular and infection microbiology · 2023Article
- Disseminated nontuberculous mycobacterial infection with cryptic immunodeficiency mimicking malignancy: a case report.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn China, the prevalence of nontuberculous mycobacteria (NTM) in isolates from mycobacterial culture-positive patients with pulmonary tuberculosis (TB) is largely unknown.
methodsWe used conventional biochemical and 16S rRNA gene sequencing to identify species of mycobacteria in specimens from patients suspected of having TB. Drug-susceptibility testing was performed on NTM isolates using the proportion method. We also determined the independent risk factors associated with infection with NTM compared with infection with Mycobacterium tuberculosis.
resultsThe overall rate of NTM isolated from mycobacterial culture-positive patients was 5.9% in this population, with a significantly increasing trend from 3.0% in 2008 to 8.5% in 2012 (P for trend <0.001). The organism most frequently identified was M. kansasii (45.0%), followed by M. intracellulare (20.8%) and M. chelonae/abscessus (14.9%). The overall proportion of isolates resistant to the four first-line anti-TB agents were 64.6% for isoniazid, 77.6% for streptomycin, 63.3% for rifampicin and 75.1% for ethambutol. The risk factors most often associated with NTM infection were older age (P for trend <0.001), being a resident of Shanghai (adjusted odds ratio [aOR], 1.48; 95% CI, 1.10-2.00), having been treated for tuberculosis (aOR, 1.64; 95% CI, 1.18-2.29), having a cavity on chest X-ray (aOR, 1.51; 95% CI, 1.16-1.96), and being sputum smear-negative (aOR, 1.59; 95% CI, 1.16-2.18).
conclusionsThe prevalence of NTM isolated in Shanghai increased between 2008 and 2012, thus clinicians should consider NTM as a possible cause of TB-like disease. Accurate species identification is imperative so that proper treatment can be administered for diseases caused by the diversity of NTM species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.